This cluster is too small to warrant a bearish read-through. Monitor for any C-suite open-market sales exceeding 0.1% of market cap, which would be a more meaningful signal. The next catalyst to watch is the upcoming quarterly earnings release for pipeline and revenue updates.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 24 $24.78entry
- T+1 · 3mo ago +0.32%α +0.00% · $24.86
- T+5 · 3mo ago −3.27%α −3.74% · $23.97
- T+20 · 8w ago +12.11%α +10.81% · $27.78
- T+59 · todayOpen
- T+60 · in 8h Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Arcutis Biotherapeutics sold a combined $170K in open-market sales over a week. Director Welgus Howard G. also exercised multiple derivative tranches for a net cash outlay of ~$32K, then sold the resulting shares at market prices. The total dollar value is only ~0.005% of ARQT's $3.2B market cap, making this a trivial cluster by proportionality standards. The sales are likely liquidity-driven following option exercises, not a bearish signal on the company's fundamentals.
Key Financial Metrics
Key Facts
- Two insiders sold a total of $170K in open-market sales over 7 days.
- Director Welgus Howard G. exercised 8,192 derivative shares (cash outlay ~$32K) and sold 4,730 shares at $26.18 for $124K.
- Total sales represent ~0.005% of ARQT's $3.2B market cap, immaterial by academic proportionality thresholds.
- No C-suite executives participated in the selling; the cluster is limited to a director and a 'See Remarks' officer.
- The derivative exercises and subsequent sales suggest liquidity/vesting-driven activity, not informed selling.
Financial Impact
Total insider sales of $170K, or ~0.005% of market cap, negligible economic impact.
Risk Factors
- Insider sales could accelerate if the stock continues to appreciate, but current levels are routine.
- No material risk identified from this cluster alone.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARQT-1787379288945 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers